Metallomics for drug development: a further insight into intracellular activation chemistry of a ruthenium(iii)-based anticancer drug gained using a multidimensional analytical approach

Metallomics for drug development: an integrated CE-ICP-MS and ICP-MS approach reveals the speciation changes for an investigational ruthenium(iii) drug bound to holo-transferrin in simulated cancer cytosol

(2013) Svetlana S. Aleksenko et al.   Metallomics

Advances of CE-ICP-MS in speciation analysis related to metalloproteomics of anticancer drugs

(2012) Andrei R. Timerbaev et al.   TALANTA

Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs

(2011) Alberta Bergamo et al.   DALTON TRANSACTIONS

FAB, ESI and MALDI Mass Spectrometric methods in the study of metallo-drugs and their biomolecular interactions

(2011) Marijana Petković et al.   Metallomics

Metall(prote)omic studies by capillary electrophoresis using separation capillary as an in-line reactor

(2011) Andrei R. Timerbaev et al.   Metallomics

Recent progress in the application of analytical techniques to anticancer metallodrug proteomics

(2011) A.R. Timerbaev et al.   TRAC-TRENDS IN ANALYTICAL CHEMISTRY

Ruthenium-based chemotherapeutics: are they ready for prime time?

(2010) Emmanuel S. Antonarakis et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A categorization of metal anticancer compounds based on their mode of action

(2009) Teresa Gianferrara et al.   DALTON TRANSACTIONS

Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR

(2009) Naniye Cetinbas et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Recent developments in ruthenium anticancer drugs

(2009) Aviva Levina et al.   Metallomics